P77.03 A Phase II Study of KN046 (bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)

C. Zhou,A. Xiong,W. Li,Z. Ma,X. Li,J. Fang,Q. Xie,Y. Fan,J. Xu,H. Van,P. Kong,F. Yang,J. Li,Y. Lu,T. Xu

DOI: https://doi.org/10.1016/j.jtho.2021.01.1161

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:KN046 is a novel bispecific antibody that blocks PD-L1 interaction with PD1 and CTLA-4 interaction with CD80/CD86. This multiple-cohort, single-arm phase II study evaluates preliminary safety and efficacy of KN046 in subjects with metastatic non-small cell lung cancer (NSCLC).